WO1996021662A1 - Utilisation de composes heterocycliques comme antioxydants, piegeurs de radicaux, agents de complexation de fe2+, protecteurs tissulaires et/ou neuroprotecteurs - Google Patents
Utilisation de composes heterocycliques comme antioxydants, piegeurs de radicaux, agents de complexation de fe2+, protecteurs tissulaires et/ou neuroprotecteurs Download PDFInfo
- Publication number
- WO1996021662A1 WO1996021662A1 PCT/SE1996/000007 SE9600007W WO9621662A1 WO 1996021662 A1 WO1996021662 A1 WO 1996021662A1 SE 9600007 W SE9600007 W SE 9600007W WO 9621662 A1 WO9621662 A1 WO 9621662A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ring
- group
- mmol
- methyl
- pharmaceutical composition
- Prior art date
Links
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 23
- 239000002516 radical scavenger Substances 0.000 title claims abstract description 16
- 239000008139 complexing agent Substances 0.000 title claims abstract description 10
- 239000004090 neuroprotective agent Substances 0.000 title description 7
- 150000002391 heterocyclic compounds Chemical class 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 107
- 238000000034 method Methods 0.000 claims abstract description 43
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 claims abstract description 13
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 9
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 9
- 229910052714 tellurium Inorganic materials 0.000 claims abstract description 9
- 230000036542 oxidative stress Effects 0.000 claims abstract description 6
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 125000003118 aryl group Chemical group 0.000 claims description 50
- 125000004429 atom Chemical group 0.000 claims description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 239000001257 hydrogen Substances 0.000 claims description 19
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 125000006575 electron-withdrawing group Chemical group 0.000 claims description 11
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 9
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 6
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 6
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 3
- 229910052805 deuterium Inorganic materials 0.000 claims description 3
- 230000004112 neuroprotection Effects 0.000 claims description 3
- 125000006413 ring segment Chemical group 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 150000001975 deuterium Chemical group 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 6
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229910018162 SeO2 Inorganic materials 0.000 abstract 1
- 229910003069 TeO2 Inorganic materials 0.000 abstract 1
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 abstract 1
- LAJZODKXOMJMPK-UHFFFAOYSA-N tellurium dioxide Chemical compound O=[Te]=O LAJZODKXOMJMPK-UHFFFAOYSA-N 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 74
- 239000000203 mixture Substances 0.000 description 66
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 54
- 238000006243 chemical reaction Methods 0.000 description 51
- 239000000047 product Substances 0.000 description 51
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 37
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 35
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 34
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 32
- 238000005481 NMR spectroscopy Methods 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 31
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 239000002904 solvent Substances 0.000 description 24
- HCIBTBXNLVOFER-UHFFFAOYSA-N diphenylcyclopropenone Chemical compound O=C1C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 HCIBTBXNLVOFER-UHFFFAOYSA-N 0.000 description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 229920006395 saturated elastomer Polymers 0.000 description 19
- -1 2- ethyl-1-hydroxy- 3-indolizinyl Chemical group 0.000 description 18
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 239000012043 crude product Substances 0.000 description 17
- 238000003818 flash chromatography Methods 0.000 description 17
- 229910052786 argon Inorganic materials 0.000 description 16
- 235000019439 ethyl acetate Nutrition 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 125000003406 indolizinyl group Chemical class C=1(C=CN2C=CC=CC12)* 0.000 description 14
- 235000006708 antioxidants Nutrition 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 12
- 239000012267 brine Substances 0.000 description 11
- 239000002244 precipitate Substances 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 10
- IJKXJZJLJSCTHE-UHFFFAOYSA-N indolizin-1-ol Chemical class C1=CC=CC2=C(O)C=CN21 IJKXJZJLJSCTHE-UHFFFAOYSA-N 0.000 description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 10
- 239000003208 petroleum Substances 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 238000001953 recrystallisation Methods 0.000 description 9
- 239000011669 selenium Substances 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000004809 thin layer chromatography Methods 0.000 description 9
- 229940086542 triethylamine Drugs 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 8
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000000539 dimer Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- 229960004132 diethyl ether Drugs 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 6
- BPQCYGPLHCSBAA-UHFFFAOYSA-N 2,3-bis(tert-butylsulfanyl)cycloprop-2-ene-1-thione Chemical compound CC(C)(C)SC1=C(SC(C)(C)C)C1=S BPQCYGPLHCSBAA-UHFFFAOYSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 150000001556 benzimidazoles Chemical class 0.000 description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 150000002431 hydrogen Chemical group 0.000 description 5
- 230000003859 lipid peroxidation Effects 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000004224 protection Effects 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- CLYHRQADKDKLAB-UHFFFAOYSA-N 2,3-bis[(2-methylpropan-2-yl)oxy]cycloprop-2-en-1-one Chemical compound CC(C)(C)OC1=C(OC(C)(C)C)C1=O CLYHRQADKDKLAB-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 206010063837 Reperfusion injury Diseases 0.000 description 4
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 4
- 239000012346 acetyl chloride Substances 0.000 description 4
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 4
- UHOVQNZJYSORNB-MZWXYZOWSA-N benzene-d6 Chemical compound [2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1[2H] UHOVQNZJYSORNB-MZWXYZOWSA-N 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- MUYSADWCWFFZKR-UHFFFAOYSA-N cinchomeronic acid Chemical compound OC(=O)C1=CC=NC=C1C(O)=O MUYSADWCWFFZKR-UHFFFAOYSA-N 0.000 description 4
- GGRQLKPIJPFWEZ-UHFFFAOYSA-N cycloprop-2-en-1-one Chemical class O=C1C=C1 GGRQLKPIJPFWEZ-UHFFFAOYSA-N 0.000 description 4
- 150000002019 disulfides Chemical class 0.000 description 4
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 4
- 229910052753 mercury Inorganic materials 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- 229960000381 omeprazole Drugs 0.000 description 4
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 4
- ALJUMASAQKRVRM-UHFFFAOYSA-N pyridine-3,4-dicarbonitrile Chemical compound N#CC1=CC=NC=C1C#N ALJUMASAQKRVRM-UHFFFAOYSA-N 0.000 description 4
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 4
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 229910021607 Silver chloride Inorganic materials 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 229910000365 copper sulfate Inorganic materials 0.000 description 3
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- YMWUJEATGCHHMB-DICFDUPASA-N dichloromethane-d2 Chemical compound [2H]C([2H])(Cl)Cl YMWUJEATGCHHMB-DICFDUPASA-N 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000001307 helium Substances 0.000 description 3
- 229910052734 helium Inorganic materials 0.000 description 3
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical class C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 2
- QLXQXHSTDJDCCD-UHFFFAOYSA-N 2,3-bis(tert-butylsulfanyl)cycloprop-2-en-1-one Chemical compound CC(C)(C)SC1=C(SC(C)(C)C)C1=O QLXQXHSTDJDCCD-UHFFFAOYSA-N 0.000 description 2
- WEGYGNROSJDEIW-UHFFFAOYSA-N 3-Acetylpyridine Chemical compound CC(=O)C1=CC=CN=C1 WEGYGNROSJDEIW-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 0 CC(Oc1c(C(*(C=C2)C(c3ccccc3)=C3c4ccccc4)=C3OC(C)=O)[n]2c(-c2ccccc2)c1-c1ccccc1)=O Chemical compound CC(Oc1c(C(*(C=C2)C(c3ccccc3)=C3c4ccccc4)=C3OC(C)=O)[n]2c(-c2ccccc2)c1-c1ccccc1)=O 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002669 organ and tissue protective effect Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 2
- GPHQHTOMRSGBNZ-UHFFFAOYSA-N pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC=C1 GPHQHTOMRSGBNZ-UHFFFAOYSA-N 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000027756 respiratory electron transport chain Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(I) nitrate Inorganic materials [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- NBRKLOOSMBRFMH-UHFFFAOYSA-N tert-butyl chloride Chemical compound CC(C)(C)Cl NBRKLOOSMBRFMH-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- DUGOFBPBCGIKGI-UHFFFAOYSA-N (2,3-diphenyl-1h-pyrrolo[1,2-c]pyrimidin-1-yl) acetate Chemical compound C=1C2=CC=CN2C(OC(=O)C)N(C=2C=CC=CC=2)C=1C1=CC=CC=C1 DUGOFBPBCGIKGI-UHFFFAOYSA-N 0.000 description 1
- OLORJFOMEDLTOM-UHFFFAOYSA-N (2,3-diphenyl-1h-pyrrolo[1,2-c]pyrimidin-1-yl)oxy-triethylsilane Chemical compound C=1C2=CC=CN2C(O[Si](CC)(CC)CC)N(C=2C=CC=CC=2)C=1C1=CC=CC=C1 OLORJFOMEDLTOM-UHFFFAOYSA-N 0.000 description 1
- GSVCQERZGWJNFM-UHFFFAOYSA-N (7-cyano-2,3-diphenylindolizin-1-yl) methanesulfonate Chemical compound N12C=CC(C#N)=CC2=C(OS(=O)(=O)C)C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 GSVCQERZGWJNFM-UHFFFAOYSA-N 0.000 description 1
- ISUQMUJWDCSSRJ-UHFFFAOYSA-N (7-cyano-2,3-diphenylindolizin-1-yl) trifluoromethanesulfonate Chemical compound N12C=CC(C#N)=CC2=C(OS(=O)(=O)C(F)(F)F)C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 ISUQMUJWDCSSRJ-UHFFFAOYSA-N 0.000 description 1
- BLZOHTXDDOAASQ-UHFFFAOYSA-N 1,2,3,3-tetrachlorocyclopropene Chemical compound ClC1=C(Cl)C1(Cl)Cl BLZOHTXDDOAASQ-UHFFFAOYSA-N 0.000 description 1
- QQBLVUBZDRATDA-UHFFFAOYSA-N 1-hydroxy-2,3-diphenylindolizine-6,7-dicarboxylic acid Chemical compound N12C=C(C(O)=O)C(C(=O)O)=CC2=C(O)C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 QQBLVUBZDRATDA-UHFFFAOYSA-N 0.000 description 1
- HXCKJAPEUYDDNL-UHFFFAOYSA-N 1-hydroxy-2,3-diphenylindolizine-7-carboxylic acid Chemical compound OC1=C2C=C(C(=O)O)C=CN2C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 HXCKJAPEUYDDNL-UHFFFAOYSA-N 0.000 description 1
- IRTQWWHBDXZDOW-UHFFFAOYSA-N 1-indolizin-1-ylethanone Chemical class C1=CC=CC2=C(C(=O)C)C=CN21 IRTQWWHBDXZDOW-UHFFFAOYSA-N 0.000 description 1
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 1
- KXPHJGWRCICEDH-UHFFFAOYSA-N 1-sulfanylidene-3h-dithiole Chemical class S=S1SCC=C1 KXPHJGWRCICEDH-UHFFFAOYSA-N 0.000 description 1
- PPFKQEVWJGRSJC-UHFFFAOYSA-N 2-(benzenesulfonylmethyl)pyridine Chemical compound C=1C=CC=CC=1S(=O)(=O)CC1=CC=CC=N1 PPFKQEVWJGRSJC-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- LZENMJMJWQSSNJ-UHFFFAOYSA-N 3H-1,2-dithiole-3-thione Chemical class S=C1C=CSS1 LZENMJMJWQSSNJ-UHFFFAOYSA-N 0.000 description 1
- GJOHLWZHWQUKAU-UHFFFAOYSA-N 5-azaniumylpentan-2-yl-(6-methoxyquinolin-8-yl)azanium;dihydrogen phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 GJOHLWZHWQUKAU-UHFFFAOYSA-N 0.000 description 1
- OQPNAIWFQMBBRH-UHFFFAOYSA-N 7-carboxy-1-oxido-2,3-diphenylindolizine-6-carboxylate;triethylazanium Chemical compound CC[NH+](CC)CC.CC[NH+](CC)CC.N12C=C(C([O-])=O)C(C([O-])=O)=CC2=C(O)C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OQPNAIWFQMBBRH-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 208000033116 Asbestos intoxication Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- YEWYHTIELQVEPW-UHFFFAOYSA-N C12=NC3=CC=CC=C3N2C(S)=C2N1C=CC=C2 Chemical compound C12=NC3=CC=CC=C3N2C(S)=C2N1C=CC=C2 YEWYHTIELQVEPW-UHFFFAOYSA-N 0.000 description 1
- MKKHBCAWMVQAAX-UHFFFAOYSA-N CC(Oc1c(cc(cc2)C#N)[n]2c(-c2ccccc2)c1-c1ccccc1)=O Chemical compound CC(Oc1c(cc(cc2)C#N)[n]2c(-c2ccccc2)c1-c1ccccc1)=O MKKHBCAWMVQAAX-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 1
- JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000031969 Eye Hemorrhage Diseases 0.000 description 1
- 208000008265 Favism Diseases 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 206010018444 Glucose-6-phosphate dehydrogenase deficiency Diseases 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 241000270878 Hyla Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 201000002772 Kwashiorkor Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 1
- DYCMFDXMRVECFC-UHFFFAOYSA-N N#CC1C=CN=CC1C#N Chemical compound N#CC1C=CN=CC1C#N DYCMFDXMRVECFC-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000004617 QSAR study Methods 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical group [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- MKDQWHJXVGCWMZ-UHFFFAOYSA-N [1-(2,3-dimethylbutan-2-yl)-2,3-diphenyl-1H-pyrrolo[1,2-c]pyrimidin-4-yl]oxy-dimethylsilane Chemical compound C(C)(C)(C(C)C)C1N(C(=C(C=2N1C=CC=2)O[SiH](C)C)C1=CC=CC=C1)C1=CC=CC=C1 MKDQWHJXVGCWMZ-UHFFFAOYSA-N 0.000 description 1
- NRTGWAAGLRTUJZ-UHFFFAOYSA-N [4-[3-(dibutylamino)propoxy]phenyl]-(2-ethylindolizin-3-yl)methanone Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CC)C=C2N1C=CC=C2 NRTGWAAGLRTUJZ-UHFFFAOYSA-N 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000002431 aminoalkoxy group Chemical group 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001466 anti-adreneric effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 206010003441 asbestosis Diseases 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229950007869 butoprozine Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000003532 cataractogenesis Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 231100000045 chemical toxicity Toxicity 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- KIGALSBMRYYLFJ-UHFFFAOYSA-N chloro-(2,3-dimethylbutan-2-yl)-dimethylsilane Chemical compound CC(C)C(C)(C)[Si](C)(C)Cl KIGALSBMRYYLFJ-UHFFFAOYSA-N 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940052303 ethers for general anesthesia Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- ITAMRBIZWGDOHW-UHFFFAOYSA-N fantofarone Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCOC1=CC=C(S(=O)(=O)C2=C3C=CC=CN3C=C2C(C)C)C=C1 ITAMRBIZWGDOHW-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- ARBOVOVUTSQWSS-UHFFFAOYSA-N hexadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCC(Cl)=O ARBOVOVUTSQWSS-UHFFFAOYSA-N 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 238000007539 photo-oxidation reaction Methods 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 150000003020 phtalazines Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960005179 primaquine Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 238000005956 quaternization reaction Methods 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000002468 redox effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 150000003346 selenoethers Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910001494 silver tetrafluoroborate Inorganic materials 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005991 sulfenylation reaction Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical group [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- LFSLMGRFMRFGOC-UHFFFAOYSA-N tert-butyl-[(2,3-diphenyl-1h-pyrrolo[1,2-c]pyrimidin-1-yl)oxy]-dimethylsilane Chemical compound C=1C2=CC=CN2C(O[Si](C)(C)C(C)(C)C)N(C=2C=CC=CC=2)C=1C1=CC=CC=C1 LFSLMGRFMRFGOC-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- DWCSXQCXXITVKE-UHFFFAOYSA-N triethyloxidanium Chemical compound CC[O+](CC)CC DWCSXQCXXITVKE-UHFFFAOYSA-N 0.000 description 1
- RQYLOOVORNJDQX-UHFFFAOYSA-N trifluoromethyl thiohypochlorite Chemical compound FC(F)(F)SCl RQYLOOVORNJDQX-UHFFFAOYSA-N 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Definitions
- the precent invention relates to the use of new and/or known compounds of a specific heterocyclic formula structure for the manufacture of a pharmaceutical composition having the effect of an antioxidant, radical scavenger, Fe 2+ complexing agent, tissue- and/or neuroprotectants, to new heterocyclic compounds having such effect and pharmaceutical compositions comprising such a compound, and to a method for the prevention or treatment of diseases in mammals, including man, caused by oxidative stress.
- the present invention is based on the finding that certain compounds comprising a specific heterocyclic formula structure have the property, in some cases after bioactivation of their precursors (for instance compounds of Formula IV) , which are also included in this invention, (e.g. hydrolysis by esterases or other enzymes in the gut and/or intestinal wall, in the liver or in plasma, in the brain/central nervous system or any other target organ) , of being easily oxidized to a persistent free radical, while at the same time detoxifying endogenous radicals.
- An alternative mode of action, among others, by which the compounds contemplated for use according to this invention may exert their action is by detoxifying non beneficial radicals prior to eventual hydrolysis. Still another mode of action may be as electron acceptors in electron transfer reactions involved in beneficial radical scavenging reactions. Fe 2+ complexation is another possible mode of action of the claimed compounds.
- Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglauco a agents. Desantis, Louis, Jr. PCT Int. Appl., 20 PP. WO 9323082 Al 931125 .
- Fantofarone (SR33557) : effects on myocardial oxygen consumption and coronary blood flow. Hodeige, D. ;
- Hassle AB and others Other known compounds have been published in patents and publications from Hassle AB and others; Benzimidazoles for alleviating stomach ulcers in swine. Baile, C. A. ;
- Timoprazole is a unique cytoprotective agent in the rat. Ruwart, M. J.; Nezamis, J . E. ; Rush, B. D. ; Lancaster, C. ; Davis, J. P.; Nichols, N. M.; Ochoa, R. Digestion 1984 30(1) 33-40. Effect of substituted benzimidazoles on acid secretion in isolated and enriched guinea pig parietal cells. Sewing, K. F. ; Harms, P.; Schulz, G. ; Hannemann, H. Gut 1983 24(6) 557- 60.
- Benzimidazole derivatives for the treatment of intestinal disorders.
- Aktiebolag Hassle, Swed. Jpn. Kokai Tokkyo Koho, 10 pp. JP 61205211 A2 860911 Showa. Substituted pyrido[l' ,2' :3 ,4] imidazo[1,2-a]benzimidazoles, their use and pharmaceutical preparations from these compounds.
- Hitzel, V.; Rackur, G.; Bickel, M. Ger. Offen. 34 pp. DE 3333314 Al 850328 .
- the molecules of the invention are cyclic ⁇ -systems which contain as a basic structural element the structure in Formula I.
- X is a member selected from the 20 group consisting of O, S, Se, Te, SO, S0 2 , SeO, Se0 2 , TeO, Te0 2 ;
- R represents a hydrogen atom, a deuterium atom or, when X is 0, S, Se or Te, a group C(0)R 8 , COOR 8 or CONR 9 R 10 ,
- R 8 is selected from the group consisting of (C--Cg)alkyl, (C j -Cg)halogenalkyl, (C 2 -Cg)alkenyl, (C 2 -Cg)alkynyl, (C-J-CJ Q )cycloalkyl, (C4-C9)cycloalkylmethyl, alkylaryl, aralkyl, aryl, alkylheteroaryl and heteroarylalkyl; and
- R" and R which are equal or different, each represents a hydrogen atom or R°, wherein R° is as defined above; or
- X and R together form a group SR 8 , SOR 8 , S0 2 R 8 , OS0 2 R 8 ,
- X is as defined above, X' is a member selected from the group consisting of O, S, Se and Te,
- R' is Ac or R as defined above, which compound can carry a substituent at any or all posi ⁇ tions, said substituent being independently selected from (C,-C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 3 -
- antioxidants include the known compound pyridofl' , 2 ' :3 ,4]- imidazo[l,2-a]benzimidazol-12-thiol, dimers of pyrido- [1' ,2' :3,4]imidazo[1,2-a]benzimidazol-12-thiol and analogs where sulfur is substituted with oxygen, selenium or tellurium, or more generally molecules of Formulas II and III and substituted derivatives thereof.
- X is as defined above; Y and Z, which are equal or different, each represents N or
- Ri and R 2 which are equal or different, are each selected from the group consisting of H, (C j -Cg)alkyl, (C 2 -
- R 10 CONR 9 R 10 .
- R3 is selected from the group consisting of hydrogen, deuterium, (C j -Cg)alkoxy, CN, CHO, C(0)R 8 , COOH and salts, esters and amides thereof or R3 represents an electron pair when Z is N;
- R 4 is equal to R j , R 2 , R3, R5 or Rg, preferably H;
- R5 and Rg which are equal or different, are each selected from unsubstituted or substituted aryl or heteroaryl groups, (C j -C j g)alkyl, (C--C j g)O-alkyl, O-aryl, (C j -C j g)S- alkyl and S-aryl;
- R 7 represents a group COR , COOR 8 or CONR 9 R , when X is 0,
- R , R , R 12 and R 13 are as defined above; or R j and R 2 together with the intervening atoms of the 6- membered ring form a 5- or 6-membered aromatic or heteroaromatic ring; or
- R and R3 together with the intervening atoms of the 6- membered ring form a 5- or 6-membered aromatic or heteroaromatic ring;
- R3 and R 4 together with the intervening atoms of the 6- membered ring form a 5- or 6-membered aromatic or heteromatic ring;
- R4 and R5 together with the intervening 3 atoms of the fused ring system form a 5- or 6-membered aromatic or heteroaromatic ring;
- R5 and Rg together with the intervening atoms of the 5-mem- bered ring form a 5- or 6-membered aromatic or heteromatic ring.
- R is preferably an electronwithdrawing group (EWG) for the indolizinols ((Y) and (Z) equals C) , and may or may not preferably be an EWG or an electrondonating group (EDG) or a hydrogen atom for the various azaindolizinols.
- EWG electronwithdrawing group
- XR 7 is SRg, SORg, S0 2 8) , where Rg is defined as above;
- XR 7 is Si(R JRJ 2 RJ ) , where RJJ, R 2 and R 1 are as defined above;
- EWGs for substitution of either the protected alcohol/phenol or the deprotected molecule - nitrile, sulphonate, sulfoxide, sulfone, sulfonamide and salts thereof and, more preferably, carboxyl groups (and esters, amides and salts thereof) are especially preferred within any one aryl ring, however, generally only one, or at most two, such EWGs will be desired. At least one EWG substituent are preferred in the indolizine series.
- EDGs electron donor groups
- a preferred group of compounds to be used according to the invention comprises compounds of formulas IV and V wherein
- X is 0; one or both of Y and Z is C;
- R j and R3 when being bound to Y and Z, respectively, rep- resenting C, represent hydrogen
- R 2 is hydrogen, CN, CHO, C(0)R 8 or COOR 8 , wherein R° is as defined above;
- R4 is hydrogen
- R5 and Rg are each phenyl and (in case of Formula IV) R ⁇ represents a group COR , wherein R 8 is as defined above.
- X, Y, Z, R j , R 2 , R3 and R4 are as defined above and
- R' 7 is H or R 7 as defined above, or
- X and R' 7 together form a group SR 8 , SOR 8 , S0 2 R 8 , OSi(R n R 12 R 13 ) , OR 8 , SR 8 , SeR 8 or TeR 8 ,
- Ph is phenyl
- R j and R 2 together with the intervening atoms of the 6- membered ring form a 5- or 6-membered aromatic or hetero ⁇ aromatic ring;
- R j and R 4 together with the intervening atoms of the 6- membered ring form a 5- or 6-membered aromatic or hetero ⁇ aromatic ring; or R 3 and R 4 together with the intervening atoms of the 6- membered ring form a 5- or 6-membered aromatic or heteromatic ring;
- X and R' 7 together form a group SR 8 , SOR 8 , S0 2 R 8 , OSi(R U R 12 R 13 ) , OR 8 , SR 8 , SeR 8 or TeR 8 , wherein R 8 , R 11 , R 12 are as defined above, Ph is phenyl, or
- R and R together with the intervening atoms of the 6- membered ring form a 5- or 6-membered aromatic or hetero- aromatic ring;
- R j and R 4 together with the intervening atoms of the 6- membered ring form a 5- or 6-membered aromatic or hetero ⁇ aromatic ring;
- R 2 and R 4 together with the intervening atoms of the 6- membered ring form a 5- or 6-membered aromatic or hetero ⁇ matic ring.
- Preferred compounds may exhibit profound therapeutic antioxidant, tissue- and/or neuroprotective effects in any of the following non limiting organs and for instance against the following non limiting disease factors/diseases/disorders, which may be associated oxidative stress: Lung: bronchopulmonary dysplasia, asbestosis, silicosis, cigarette smoke, idiopathic pulmonary fibrosis, cystic fibrosis, ARDS, asthma, COPD, inhaled oxidants (N0 ⁇ , O3) .
- Brain hyperbaric oxygen, Parkinson's disease, Alzheimer's disease, neurotoxins (for instance, aluminum, MPTP, 6-hydroxydopamine) , vitamine E deficiency, stroke, intracranial hemorrhage, subarachnoidal hemorrhage, braintrauma, cerebral malaria, cerebral trpanosomiasis, ALS, neuronal ceroid lipofuscinoses.
- Kidney autoimmune nephrosis (inflammation) , chemicals (aminoglycosides, heavy metals, cis-Platin) , kidney transplantation (tissue protection) .
- Cardiovascular system heart infarction, heart stop, reperfusion damage, heart transplantation (tissue protection) .
- Gastrointenstinal system inflammatory bowel disease, reperfusion damage, chemicals (nonsteroidal antiinflammatory agents, ions) , emesis.
- Liver liver cirrhosis, chemicals (halogenated hydrocarbons, iron, paracetamol, ethanol, quinones) , endotoxin, reperfusion damage, liver transplantation (tissue protection) .
- Blood thalassemia, anemia (sickle cell, favism, Fanconi's) , chemicals (phenylhydrazine, sulfonamides, lead, primaquine) , malaria, protoporphyrine photooxidation.
- Eye cataractogenesis, ocular hemorrhage, photochemical retiopathy, retrolental fibroplasia.
- Muscle multiple sclerosis, muscular dystrophy, exercise.
- Skin radiation (ionizing, solar), thermal injury, chemicals (i. e. tetracyclines) , contact dermatitis, porphyria, photodynamic therapy, psoriasis, skin rashes.
- Miscellaneous ageing, radiation injury, inflammation in general, rheumatoid arthritis, chemicals (alloxan, radiosensitizers) , alcoholism, nutritional deficiencies (Kwashiorkor) .
- steric hindrance of neighboring ring sites in order to enhance low reactivity of the byproducts (azaindoliziyls or indolizinyls) produced during the beneficial reactions, is preferably effected by substitution with bulky substituents such as for instance t-butylthio, t-butoxy or t-butyl substituents.
- any alkyl or alkenyl moiety conveniently will contain up to 6, especially up to 4, carbon atoms and any aryl moiety will preferably contain 5 to 7 ring atoms in the ring or any aromatic ring and especially preferably will comprise an aromatic ring with 0, 1 or 2 further aromatic rings fused directly or indirectly thereto.
- Preferred indolizine compounds include those wherein R is an EWG, especially a cyano, a formyl or keto functionality, an ester or amide or a carboxylic acid group or a salt thereof.
- Preferred azaindolizine compounds do include those wherein R 2 is hydrogen.
- R j hydrogen, alkoxy and carboxylic acid and salts, esters and amides thereof for R 2 : cyano, formyl, keto, carboxylic acid and salts, esters and amides thereof for R : hydrogen, alkoxy and carboxylic acid and salts, esters and amides thereof for R 4 : hydrogen and, in case of compounds of Formulas IV and V, for R j and R and intervening atoms in the 6-membered ring together: a 5- or 6-membered aromatic or hereoaromatic ring; for R and R3 and intervening atoms in the 6-membered ring together: a 5- or 6-membered aromatic or heteroaromatic ring; for R3 and R4 and intervening atoms in the 6-membered ring together: a 5- or 6-membered aromatic- or heteroaromatic ring; for R 4 and R5 and the intervening 3 atoms a 5- or 6- membered aromatic- or heteroaromatic ring which may or may not
- Cyclic ⁇ t-system indolizines, indolizinols and the protected forms of the indolizinols are widely known from the literature and those suitable for use according to the invention may be prepared by the methods described in the literature. Substitution along the lines discussed above may be achieved using methods known from the literature or by using methods analogous to those discussed in
- Photographic elements capable of providing oxoindolizine and oxoindolizinium dye compounds Eur . Pat . Appl . 1981 EP 68880 Al 830105. Inion, H. ; Rosseels, G. Indolizine derivatives, their salts, their pharmaceutical or veterinary compositions and method for treating pathological syndromes. Braz . Pedido 1979 PI 810609. Rosseels, G. ; Nokin, P. Indolizine derivatives and their therapeutic use. Eur . Pat . Appl . 1979 EP 22762 810121. Pohjala, E. K. Indolizine derivatives. Part XI.
- Indolizines from the acylative cyclization of 3-(2-pyridyl)-2-propen-l-ones and related compounds Acta Chem . Scand. , B 30 (6) 1976 512-516. Pohjala, E. Indolizine derivatives.
- III Cyclization of the aldol product of 2-pyridinecarbaldehyde and .beta.-dimethylamino (or .beta.-hydroxy) ketones.
- the claimed compounds and the known compounds may themselves may be prepared by methods conventional in the art or analogous to those described in EPA 84402207.9, US 4,446,223, EPA 82303386.5, Tet . Lett . 1981 (22) 3569-3572, J. Org. Chem . 1986 (51) 4639-4644, J . Org . Chem . 1989 (54) 3652-3660, J . Org. Chem . 1989 (54) 3660-3664 and J. Org . Chem . 1991 (56) 5594-5598, WO 9302710, WO 92-EP1792, WO 9302711, WO 92-EP1793.
- the indolizinols and the azaindolizinols may themselves be prepared by methods conventional in the art.
- a suitable cyclopropenone is conveniently reacted with an appropriately substituted pyridine, pyrimidine or triazine, following for example the procedures described by Wadsworth et al. in ret. Lett . 1981 (22) 3569-3572 and J. Org. Chem . 1986 (51) 4639-4644, J. Org . Chem . 1989 (54), 3652-3660 J. Org. Chem . 1989 (54) 3660-3664, and J. Org . Chem . 1991 (56) 5594-5598.
- the protected indolizinols and the protected azaindolizinols may themselves be prepared by methods conventional in the art.
- a protected (aza)indolizinol a suitable cyclopropenone is conveniently reacted with an appropriately substituted pyridine, pyrimidine or triazine, and thereafter the OH functionality is protected as for instance an actetate, following for example the procedures described by Wadsworth et al. in Tet. Lett.
- Hydrogenated indolizines for instance indolizinyl alkaloids like castanospermine or similar substances also represent useful reagents in the synthesis of the indolizinols. These hydrogenated substances can potentially be dehydrogenated and/or dehydrated to the indolizinols. See for instance: J.A.C.S. 1990, 8100; Tet. Lett. 1990 5689; Tet. Lett. 1990 7109; Tet. Lett. 1990 6949, Barton, D. H. R. et al. Tet. Lett. 1994 (35) 9157- 9158, Gurjar, M. K. et al. Tet. Lett. 1994 (35) 8871-8872. Martin-Lopez_ M. J. et al. Tet. Lett. 1994 (35) 8843-8846.
- novel compounds of Formula IV wherein one of Y and Z is C and the other is N;
- R is hydrogen, when Y is C, and an electron pair, when Y is N;
- R 5 and Rg are each phenyl; and X and R together form a group OSi(R 11 R 12 R 13 ) , wherein R 11 ,
- R ⁇ and R* 3 are as defined above in connection with Formula
- compositions comprising said compounds together with a pharmaceutically acceptable carrier and the use of said compounds for the manufacture of a pharmaceutical composition having the effect of an antioxidant, radical scavenger, Fe 2 -complexing agent, tissue and/or neuroprotectant.
- a method for the treatment of diseases in mammals comprising administering to said mammal of an effective dose of a compound of any of Formulas I to VII as defined above.
- An example of application of the method according to the invention is the administration of the compound for the purpose of neuroprotection and for the prevention or treatment of stroke or a neurodegenerative disease.
- Examples of neurodegenerative diseases to be prevented or treated are Alzheimer's disease and Parkinson's disease.
- the compounds according to the invention can be formulated into pharmaceutical composition in any conventional way for the preparation of such compositions.
- Formulation aids such as are conventional for therapeutic and diagnostic compositions in human or veterinary medicine.
- the media may for example include solubilizing agents, emulsifiers, viscosity enhancers, buffers, etc.
- the media may be in forms suitable for parenteral (e.g. intravenous) or enteral (e.g. oral) application. Solutions, suspensions and dispersions in physiologically tolerable media will generally be preferred.
- Compounds of Formulas I-VII may be encapsulated, e.g. in gastric juice resistant capsules containing a medium in which they are stable, alternatively, the compounds may be presented as an encapsulated freeze dried powder in a soluble capsule. Such formulations might conveniently be dissolved shortly before in vivo use.
- Diphenylcyclopropenone (Aldrich 17,737-7) (0.500 g, 2.42 x rt . . . . 10 "J mol) and isonicotinic acid (Aldrich 1-1,750-8) (0.2985 g 2.424 x 10 "J mol) were added in solid form to a carefully dried reaction flask.
- the flask was equipped with a septum and the flask was evacuated three times with addition of nitrogen after each evacuation.
- Chlorobenzene (Aldrich 27,064-4) (5 mL) was added with a gas tight syringe. The stirred mixture was cooled to 0 * C.
- Triethylamine (Aldrich 23,962-3) (0.3379 mL, 2.42 x 10 "3 mol) was added dropwise with a gas tight syringe. The resulting mixture was stirred at ambient temperature for 2 days. The color of the mixture changed to yellow and then to green. The solvent was removed on a rotary evaporator, and the resulting semisolid was redissolved in hot ethanol and water. After cooling to ambient temperature, the product was filtered and washed with diethylether and dried in vacuum. All these operations were performed under an atmosphere of N 2 .
- the reaction mixture was stirred at ambient temperature for 2.5 hours, while the title compound precipitated.
- the mixture was cooled to about 0 'C and the product isolated by filtration under N 2 .
- the product was washed with minute amounts of methanol and some diethyl ether and dried.
- the product was identified by mass spectrometry; DCI probe and electron impact conditions identified the heterocyclic part and *H NMR identified the ammonium part.
- the yellow/green (indolizinoleeee/indolizinyl) product was filtered under N2 and washed with small amounts of tetrahydrofuran and petrol ether. More solids formed in the filtration flask and were also collected. The products were identified as the title compound based on mass spectrometry.
- 3,4-Pyridinedicarboxylic acid (0.4051 g, 2.424 10 "3 mol) , diphenylcyclopropenone (0.500 g, 2.424 x 10 "3 mol) and N- methylglucamine (0.9404 g, 4.848 x 10 " -* mol) were stirred in a mixture of tetrahydrofuran (10 mL, degassed with helium) and methanol (3 mL, degassed with helium) at ambient temperature for 24 hours. The solvent was removed and the product triturated with diethyl ether and methanol and dried.
- Diphenylcyclopropenone (0.319 g, 1.55 mmol) and 3,4- dicyanopyridine (0.200 g, 1.55 mmol) were mixed in a dry, argon filled reaction flask. Chlorobenzene (2.5 mL) (oxygen free) was added, and the reaction was heated to 130 "C. After 2 h the heating was stopped and the reaction was allowed to reach room temperature.
- Petroleum ether 40-60 * C (2.5 mL) was added in order to obtain a complete precipitate of the product. The solvent was filtered off and the precipitate was washed with petroleum ether. The crude product was stirred with chloroform (30 mL) for 1 h. The dark chloroform solution was filtered off leaving the title product as a yellow precipitate.
- 1,1'-(2,2' ,3,3'-tetra-t-butylthio-6,6' ⁇ '-tetracyano- diindoli zine)-disulfide is treated with a reducing agent in an appropriate solvent until all disulfide is consumed.
- the reaction is stopped and the product is isolated by chromatography or recrystallization, or by a combination thereof.
- l,l'-(2,2',3,3-tetra-t-butylthio-7,7' ,8,8'-tetracyano- diindoliz ine)-disulfide is treated with a reducing agent in an appropriate solvent until all disulfide is consumed.
- the reaction is stopped and the product is isolated by chromatography or recrystallization, or by a combination thereof.
- Bis(t-butylthio)cyclopropenethione and pyridine-3,4- dicarboxylic acid are mixed in a dried, argon filled reaction flask. A dry degassed solvent is added. To the mixture is added triethylamine. The reaction is stirred until no more product is obtained. The product is isolated either by chromatography or by recrystallization, or by a combination thereof.
- EXAMPLE 14 l-Mercapto-2 ,3-di-t-butylthio-6,7-di(trie hyla monium- carboxyla te) indolizine.
- Bis(t-butylthio)cyclopropenethione and pyridine 3,4- dicarboxylic acid are mixed in a dried, argon filled reaction flask. A dry degassed solvent is added. To the mixture is added triethylamine. The reaction is stirred until no more product is obtained. The product is isolated either by chromatography or by recrystallization, or by a combination thereof.
- 1,2-Di-tert-butoxycyclobutenedione is dissolved in diethyl ether and photolyzed under nitrogen by a mercury high pressure lamp through quartz glass for 2-8 h depending on the quality of the mercury lamp.
- the title compound produced is purified by HPLC-RP, recrystallization or by distillation at low pressure, or by a combination of this techniques. (See E. V. Dehmlow Chem. Ber. 121, 569, 1988).
- 2,3-Di-tert-butoxycyclopropenone and 3,4-dicyanopyridine are mixed in a dry, argon filled flask.
- a solvent such as chlorobenzene (oxygen free) is used.
- the product is purified by chromatography or recrystallization, or by a combination of these techniques.
- 1,2-Di-tert-butoxycyclobutenedione is dissolved in diethyl ether and photolyzed under nitrogen by a mercury high pressure lamp through quartz glass for 2-8 h depending on the quality of the mercury lamp.
- the title compound produced is purified by HPLC-RP, recrystallization or by distillation at low pressure, or by a combination of this techniques. (See E. V. Dehmlow Chem. Ber. 121, 569, 1988).
- 2,3-Di-tert-butoxycyclopropenone and 3,4-dicyanopyridine are mixed in a dry, argon filled flask.
- a solvent such as chlorobenzene (oxygen free) is used.
- the product is purified by chromatography or recrystallization, or by a combination of these techniques.
- the mixture was stirred for 1 h at 0 * C, then 15 min at ambient temperature.
- the mixture was then diluted with chloroform until 100 mL total volume and washed with saturated aqueous copper sulfate (4 x 30 mL) and sat. aq.
- Example 38 The compound obtained in Example 38 (80 mg, 0.34 mmol) was dissolved in CH 2 C1 (8 mL) and the solution was degassed with N 2 (g) and then cooled to 0°C. (CF3S0 2 ) 2 0 (0.2 mL) was added and then Et3N (0.1 mL) .
- the solvents of reaction mixture were evaporated under reduced pressure and the residue was redissolved in CH 2 C1 2 and Si0 2 gel was added to the flask and the solvent was evaporated under reduced pressure to leave the raw product evenly distributed on the Si0 2 particles, which were applied at the top of a dry packed Si0 2 column. Elution with hexane:EtOAc (4:1) gave fractions with pure product. These fractions were collected, the solvent was evaporated under reduced pressure to leave a white solid (59 mg) , melting at 132- 133°C.
- Example 38 To the compound obtained in Example 38 (50 mg, 0.21 mmol) was added CH 2 C1 2 (3 mL) and then Et N (2 drops) and the solution was degassed with N (g) and then cooled to 0°C. pH-N(CF3S0 2 ) 2 (100 mg, 0.31 mmol) was added. The reaction mixture was stirred at room temperature overnight.
- Example 38 The compound obtained in Example 38 (23.7 mg, 0.100 mmol) was dissolved in THF (5 mL) and one drop of Et 3 N and methanesulfonyl chloride (7.7 ⁇ L, 0.1 mmol) were added. The reaction mixture was stirred for 2 h in room temperature and then quenched with the addition of 10% NaOH and extracting with EtOAc.
- Example 38 The compound obtained in Example 38 (23.7 mg, 0.100 mmol) was dissolved in THF (5 mL) and one drop of Et 3 N and methanesulfonyl chloride (7.7 ⁇ L, 0.1 mmol) were added. The reaction mixture was stirred for 2 h at room temperature and then quenched with the addition of 10% NaOH and extracting with EtOAc.
- Example 45 1-Methanesulfonyloxy-2,3-di-phenyl-7-cyanoindolizine was synthesized according to the synthesis of Example 45, using methanesulfonylchloride as the sulfonating agent. According to GC-MS all starting material was consumed and a new spot
- the compounds according to in the present invention are stable structures which form cations, stable cation radicals or stable radicals upon oxidation. They constitute potent antioxidants as measured by inhibition of Fe 2+ - ascorbate induced lipid peroxidation in vitro. These properties suggest that the. compounds of the invention have a potential use in the protection or treatment of ischemic or reperfusion injury, particularly cerebral and cardiac ischemia/infarct, atherosclerosis, thrombosis, embolism,
- Parkinson's disease ageing. Alzheiner's disease, neoplasms and toxicity of anti-neoplastic drugs, immunosuppresive agents and inflammation including allergic-inflammatory conditions like bronchial asthma and rheumatoid arthritis. Other potential applications are chemoprevention against chemical toxicity or radiation damage.
- the compounds are not appreciably activated by UV light making them candidates for use in skin care products.
- the most remarkable feature of the compounds of the invention is their efficacy as free-radical scavengers or antioxidants.
- An assay system measuring the concentration of the compounds of formula I required to inhibit lipid peroxidation by 50% (IC 50 ) was used.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne la nouvelle utilisation de composés de formule (I), dans laquelle X représente un élément choisi dans le groupe constitué de O, S, Se, Te, SO, SO2, SeO, SeO2, TeO, TeO2; cette nouvelle utilisation est destinée à la fabrication d'une composition pharmaceutique ayant l'effet d'un antioxydant, d'un piégeur de radicaux, d'un agent de complexation de Fe2+, et de protecteur tissulaire et/ou de neuroprotecteur. L'invention porte également sur des nouveaux composés englobés par la formule (I) et des compositions pharmaceutiques les contenant, ainsi qu'une méthode de prévention ou de traitement de maladies induites par le stress oxydatif.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU44614/96A AU4461496A (en) | 1995-01-09 | 1996-01-09 | The use of heterocyclic compounds as antioxidants, radical scavengers, fe2+ complexing agents, tissue- and/or neuroprotectants |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9500051A SE9500051D0 (sv) | 1995-01-09 | 1995-01-09 | Antioxidants, tissue- and/or neuroprotectants |
SE9500051-9 | 1995-01-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996021662A1 true WO1996021662A1 (fr) | 1996-07-18 |
Family
ID=20396768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1996/000007 WO1996021662A1 (fr) | 1995-01-09 | 1996-01-09 | Utilisation de composes heterocycliques comme antioxydants, piegeurs de radicaux, agents de complexation de fe2+, protecteurs tissulaires et/ou neuroprotecteurs |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU4461496A (fr) |
SE (1) | SE9500051D0 (fr) |
WO (1) | WO1996021662A1 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6525053B1 (en) | 1997-08-22 | 2003-02-25 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
US7001895B2 (en) | 1997-08-22 | 2006-02-21 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
WO2007113226A1 (fr) * | 2006-03-31 | 2007-10-11 | Novartis Ag | Composés organiques |
US8471005B2 (en) | 2008-12-19 | 2013-06-25 | Cephalon, Inc. | Pyrrolotriazines as ALK and JAK2 inhibitors |
US8835441B2 (en) | 2005-05-20 | 2014-09-16 | Amgen Inc. | Heterobicyclic metalloprotease inhibitors |
WO2024059220A3 (fr) * | 2022-09-15 | 2024-05-02 | Vanderbilt University | Composés à noyau 6,5 southwestern utilisés en tant que modulateurs allostériques négatifs du mglu5 et leurs méthodes de production et d'utilisation |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0138034A1 (fr) * | 1983-09-15 | 1985-04-24 | Hoechst Aktiengesellschaft | Pyrido[1,2-c]imidazo[1,2-a]benzimidazoles substitués, procédé pour leur préparation, leur application et compositions pharmaceutiques à base de ces composés |
-
1995
- 1995-01-09 SE SE9500051A patent/SE9500051D0/xx unknown
-
1996
- 1996-01-09 AU AU44614/96A patent/AU4461496A/en not_active Abandoned
- 1996-01-09 WO PCT/SE1996/000007 patent/WO1996021662A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0138034A1 (fr) * | 1983-09-15 | 1985-04-24 | Hoechst Aktiengesellschaft | Pyrido[1,2-c]imidazo[1,2-a]benzimidazoles substitués, procédé pour leur préparation, leur application et compositions pharmaceutiques à base de ces composés |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6525053B1 (en) | 1997-08-22 | 2003-02-25 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
US7001895B2 (en) | 1997-08-22 | 2006-02-21 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
US7115591B2 (en) | 1997-08-22 | 2006-10-03 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
US8835441B2 (en) | 2005-05-20 | 2014-09-16 | Amgen Inc. | Heterobicyclic metalloprotease inhibitors |
WO2007113226A1 (fr) * | 2006-03-31 | 2007-10-11 | Novartis Ag | Composés organiques |
JP2009531390A (ja) * | 2006-03-31 | 2009-09-03 | ノバルティス アクチエンゲゼルシャフト | 有機化合物 |
US8097617B2 (en) | 2006-03-31 | 2012-01-17 | Novartis Ag | Organic compounds |
US8471005B2 (en) | 2008-12-19 | 2013-06-25 | Cephalon, Inc. | Pyrrolotriazines as ALK and JAK2 inhibitors |
WO2024059220A3 (fr) * | 2022-09-15 | 2024-05-02 | Vanderbilt University | Composés à noyau 6,5 southwestern utilisés en tant que modulateurs allostériques négatifs du mglu5 et leurs méthodes de production et d'utilisation |
Also Published As
Publication number | Publication date |
---|---|
AU4461496A (en) | 1996-07-31 |
SE9500051D0 (sv) | 1995-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI63587C (fi) | Foerfarande foer framstaellning av anti-inflammatoriska halogenerade 4-hydroxi-2-alkyl-3-karbamoyl-2h-tieno-1,2-tiazin-1,1-dioxidderivat | |
US5885996A (en) | Antiproliferative quinazolines | |
RU2049779C1 (ru) | Производные 4-аминофенола или их n-алкильные или солевые производные, проявляющие противовоспалительную активность | |
EP0839136B1 (fr) | DERIVES DE BENZO[g]QUINOLEINE | |
WO1992009586A1 (fr) | Inhibiteur d'oxygene actif | |
EP0555824A1 (fr) | Dérivés de benzimidazolylalaninamide N-alpha-arylsulphonyl substitués, médicaments les contenant et procédés pour leur préparation | |
EP3684772B1 (fr) | Dérivés d'iminopyrimidine cycliques utilisés en tant qu'inhibiteurs de kinases | |
SK160899A3 (en) | Ergoline derivatives and their use as somatostatin receptor antagonists | |
WO2004085440A1 (fr) | Derives de benzofuro-1,4-diazepin-2-one | |
JP2010502606A (ja) | カルシウムチャンネル遮断薬としてのインドロキノリン化合物 | |
EP1446399B1 (fr) | Derives de piperazine ayant une activite antagoniste sst1 | |
CN114790169A (zh) | 四氢喹啉相关二环类化合物及其应用 | |
EP1572698B1 (fr) | Derives de 3,4-dihydro-thieno¬2,3-d pyrimidin-4-one 3-substitues, leur preparation et leur utilisation | |
US20230219935A1 (en) | 4-(n-methyl) aminopiperidine myricetin derivative containing dithiocarbamate, preparation method and application | |
KR870001144B1 (ko) | 삼환 옥스인돌 카복스아미드 유도체의 제조방법 | |
WO1996021662A1 (fr) | Utilisation de composes heterocycliques comme antioxydants, piegeurs de radicaux, agents de complexation de fe2+, protecteurs tissulaires et/ou neuroprotecteurs | |
CA2474848A1 (fr) | Nouveaux tyloindicines et composes s'y rapportant, compositions pharmaceutiques et methodes | |
AU2004245198B2 (en) | Indole derivatives with apoptosis-inducing effect | |
CA3079804A1 (fr) | Derives de la dihydropyridine utilises comme modulateurs des recepteurs des androgenes et des glucocorticoides | |
HUT68733A (en) | Novel thienothiazine derivatives and process for preparing them | |
CA2598988C (fr) | Derive de cyclohepta[b]pyridine-3-carbonylguanidine et produit pharmaceutique contenant ledit derive en tant qu'inhibiteur des nhe | |
JP6301474B2 (ja) | 癌および炎症性疾患を処置するための新規化合物 | |
US6602865B1 (en) | Pyridazino(4,5-b)(1,5)oxazepinone, -thiazepinone and -diazepinone compounds | |
JPS5948480A (ja) | 麦角アルカロイド | |
US5130301A (en) | Pyrrolo (1,2-a) thieno (2,3-f) (1,4)-diazepines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |